Co-Diagnostics Will Evaluate Ebola Testing Workflow
The company plans to integrate its PCR platform with new sample-preparation technology for decentralized testing.
Updated on Sept. 21, 2026 in Biotech
Co-Diagnostics will evaluate a potential integration between its PCR platform and ReadyGo Diagnostics' sample-preparation technology to improve Ebola detection. The development remains in the research-stage and the PCR platform is currently not authorized for sale.
Why it matters
Streamlining molecular testing for decentralized use is critical for accelerating the transition from early warning systems to active outbreak response. The collaboration aims to address logistical challenges posed by the ongoing Ebola outbreak in Africa.
The initiative seeks to combine the Co-Dx PCR platform with GoCollect technology to enable blood-based molecular testing. This workflow aims to decentralize diagnostics, though the platform lacks current FDA clearance or commercial availability.
The players
Co-Diagnostics
A Salt Lake City-based molecular diagnostics company that develops PCR platforms and specialized viral screening tests.
Seth Egan
The Chief Commercialization Officer for Co-Diagnostics who leads the firm's strategic partnerships and technology rollouts.
ReadyGo Diagnostics
A developer of specialized sample-preparation technology designed to enable decentralized diagnostic testing workflows.
Global Health Technologies Coalition
An advocacy organization focused on advancing research and policy for neglected health threats and outbreak responses.
The details
The collaboration focuses on creating a streamlined workflow that connects sample preparation with nucleic acid amplification. By utilizing GoCollect — a proprietary sample-preparation technology designed for blood-based molecular diagnostics — the partnership intends to detect viral genetic material in decentralized settings. This process is intended to support the Bundibugyo virus and pan-Ebola tests originally developed by CoSara Diagnostics, a joint venture involving Co-Diagnostics.
Timeline
September 21, 2026: Co-Diagnostics announces its participation in the health roundtable.
September 22, 2026: The roundtable discussion convenes in New York City.
The Tech Race
The initiative aligns with broader efforts to standardize decentralized diagnostic tools for rapid outbreak management. It follows an evaluation request by the Centre for Cellular and Molecular Platforms to validate Bundibugyo virus testing capabilities.
The proposed diagnostic workflow is currently in research-stage and remains unavailable for commercial use. Clinicians and field labs must wait for future regulatory authorization and validation results before these tools can be deployed in outbreak environments.
The takeaway
The success of this diagnostic workflow depends on the integration results between the Co-Dx PCR platform and GoCollect technology. Watch for future performance benchmarks and regulatory milestones following the ongoing evaluation of these components.
Further reading
For more updates on diagnostic innovations, visit the Biotech section.
